Regulus Therapeutics Inc.

Novartis has posted a healthy set of financials for the second quarter with strong growth for its new cancer therapies and Entresto, and is raising its earnings guidance for 2025 despite imminent gene

Novartis is making another push into renal disease with the acquisition of antisense oligonucleotide-focused Regulus Therapeutics, which is ready to move its lead candidate farabusen into Phase III de

Competition to develop new treatments for autosomal dominant polycystic kidney disease (ADPKD) is ramping up, with Vertex ready to begin trials of a potential disease modifying treatment – but rival

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte